Walter Reed Project
Welcome,         Profile    Billing    Logout  
 2 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ogutu, Bernhards
NCT02251704: Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

Completed
4
54112
RoW
Blood sampling, Assessment of body temperature
GlaxoSmithKline, The PATH Malaria Vaccine Initiative (MVI)
Malaria, Malaria Vaccines
07/24
07/24
NOVATION-1, NCT04669015: Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19

Recruiting
3
914
Canada, RoW
Novaferon, Standard of Care, Placebo
Genova Inc.
Covid19
08/22
08/22
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
RESOLVE, NCT05561140: Resolution of Sickle Cell Leg Ulcers With Voxelotor

Terminated
3
88
RoW
Voxelotor Oral Tablet, Placebo
Pfizer
Sickle Cell Disease, Leg Ulcers
06/24
10/24
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
CALINA, NCT04300309: Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Terminated
2/3
28
RoW
artemether:lumefantrine (2.5 mg:30 mg)
Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP), Medicines for Malaria Venture (MMV), Switzerland, Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso, Institut de Recherche en sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Burkina Faso
Plasmodium Falciparum Malaria
07/23
05/24
EPI-MAL-003, NCT03855995: A Study to Evaluate the Safety, Effectiveness and Impact of the GlaxoSmithKline Biologicals' Malaria Vaccine- RTS, S/AS01E in Young Children in Sub-Saharan Africa

Recruiting
N/A
78000
RoW
Whole blood sample
GlaxoSmithKline
Malaria, Malaria Vaccines
05/25
05/25

Download Options